Exchange: NASDAQ·Updated 10:34 AM EDT
News
all
press releases
Why Did UPB Stock Plunge 40% Today?
The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma.
Stocktwits
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +30.77% and +1.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.